<DOC>
	<DOC>NCT00364832</DOC>
	<brief_summary>This study will determine the appropriate dose and frequency of administration of sc Mircera maintenance therapy in dialysis patients with chronic renal anemia who were previously receiving sc epoetin alfa or beta. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patients &gt;=18 years of age; chronic renal anemia; on dialysis (hemodialysis or peritoneal dialysis) therapy for at least 3 months; receiving sc epoetin alfa or beta for at least 3 months prior to the runin period. women who are pregnant, breastfeeding or using unreliable birth control methods; use of any investigational drug within 30 days preceding the runin phase, or during the runin or study treatment period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>